NASDAQ:CALT Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis $40.00 0.00 (0.00%) As of 06/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CALT alerts:Sign Up Key Stats Today's Range$40.00▼$40.0050-Day Range$40.00▼$40.0052-Week Range$15.25▼$43.00VolumeN/AAverage Volume10,339 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calliditas Therapeutics AB (publ) is a Sweden-based biopharmaceutical company dedicated to the development and commercialization of novel therapies for rare immunologic and renal diseases. The company’s scientific focus centers on targeting the underlying causes of immune-mediated conditions with oral and biologic formulations. By leveraging proprietary drug delivery technologies, Calliditas aims to bring differentiated treatments to patients who currently have limited therapeutic options. The company’s lead product, Tarpeyo® (budesonide) delayed-release capsules, received U.S. Food and Drug Administration (FDA) approval in October 2021 for the treatment of adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression. Calliditas holds exclusive commercial rights for Tarpeyo in North America and several other territories, and it continues to pursue regulatory submissions and market access efforts in Europe and select international markets. In parallel, the company is advancing a preclinical pipeline of novel immunomodulatory compounds aimed at expanding its rare disease portfolio. Founded in 2004 and headquartered in Stockholm, Calliditas Therapeutics maintains operations across Europe and North America, supported by a corporate office in Boston to oversee U.S. commercialization activities. The company is publicly traded on the Nasdaq Stockholm exchange as well as on the Nasdaq Global Select Market in the United States under the ticker symbol CALT. Calliditas is led by an experienced management team with backgrounds in biopharmaceutical research, regulatory affairs and commercial strategy, positioning the company to execute its growth plans in the global rare disease arena.AI Generated. May Contain Errors. Read More Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CALT Stock News HeadlinesCalliditas Therapeutics’ Setanaxib Study: A Potential Game-Changer for Alport SyndromeAugust 14, 2025 | msn.comCalliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.June 22 at 1:00 AM | Porter & Company (Ad)Calliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comDelisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSeptember 3, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comSee More Headlines CALT Stock Analysis - Frequently Asked Questions How have CALT shares performed this year? Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the start of the year. Since then, CALT shares have increased by 0.0% and is now trading at $40.0001. How were Calliditas Therapeutics AB (publ)'s earnings last quarter? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. The firm earned $52.36 million during the quarter, compared to the consensus estimate of $42.89 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 212.04% and a negative net margin of 30.18%. Read the conference call transcript. When did Calliditas Therapeutics AB (publ) IPO? Calliditas Therapeutics AB (publ) (CALT) raised $81 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 4,153,385 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager. How do I buy shares of Calliditas Therapeutics AB (publ)? Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calliditas Therapeutics AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Target (TGT) and Company Calendar Last Earnings8/13/2024Today6/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALT CIK1795579 Webwww.calliditas.se Phone46-0-841-130-05FaxN/AEmployees180Year Founded2004Profitability EPS (Trailing Twelve Months)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.96 million Net Margins-30.18% Pretax Margin-29.40% Return on Equity-212.04% Return on Assets-27.96% Debt Debt-to-Equity Ratio9.44 Current Ratio2.69 Quick Ratio2.59 Sales & Book Value Annual Sales$1.60 billion Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book37.74Miscellaneous Outstanding Shares29,790,000Free Float29,135,000Market Cap$1.19 billion OptionableNo Data Beta1.77 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CALT) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredThe U.S. Government Just Turned Tax Dollars1 into 407% GainsThe U.S. Government has quietly built a stock portfolio that's up 278% in less than nine months - 26 times bet...Weiss Ratings | SponsoredA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....InvestPub | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
